Mission Bio has launched new multiplexing features for its Tapestri platform, saying they will make single-cell technology more affordable and accessible to the biomedical community.
Researchers can combine several samples into a single experiment, reducing the per-sample costs for single-cell DNA and protein multiomic analysis by up to 60%, the company said. This would help reduce the barrier to entry for academic researchers and “de-risk the adoption for biopharma,” Mission Bio said in a statement.
“Our new sample multiplexing features will help lower the per-sample costs of single-cell DNA sequencing and single-cell DNA plus protein multiomics, so researchers can decrease resource and labor usage and achieve higher throughput and cost-efficiency without sacrificing quality,” said Anjali Pradhan, chief product officer of Mission Bio.
Tapestri is a single-cell technology platform with multiomics capability used for purposes including identifying rare cell populations and understanding mechanisms of therapeutic resistance and response.
Two new sample multiplexing capabilities are designed to allow users to combine and analyze up to three samples per experiment. Sample multiplexing can be achieved by antibody hashing powered by antibody oligo conjugates (AOCs) from Biolegend, or by genotyping, which uses the genetic information of the relevant variants obtained by bulk sequencing to distinguish samples.
Mission Bio, based in San Francisco and founded in 2014, said that higher throughput would allow for more statistically significant studies.
In a statement, Ilaria Iacobucci, PhD, principal scientist at the Department of Pathology at St. Jude Children’s Research Hospital, said multiplexing capabilities make single-cell technology more accessible.
“Single-cell characterization in preclinical and clinical therapeutic studies is crucial. Collecting therapeutic effects at the cellular resolution can serve as indicators of successful target inhibition and efficacy in the clinical setting, especially for pediatric cancers and hematological malignancies,” Iacobucci said.
